

REMARKS

A. Status of the Claims

Claims 1-7, 9-19 and 26-43 have been canceled. Claims 8, 20, 23-25, 44-46, 48-55 have been amended. Claim 56 has been added – support for the E75 epitope can be found throughout the specification. Claims 8, 20-25 and 44-56 are pending, of which claims 25, 44-45, 48-50, 52-55 are withdrawn.

B. Drawings

Applicants apologize for the failure to include the corrected drawings. The corrected drawings are now enclosed.

C. Section 112, First paragraph (Written Description/Enablement)

With respect to the rejection of claim 27 under 35 U.S.C. § 112, first paragraph, it is respectfully noted that claim 27 has been canceled and thus the rejection is now moot.

D. Section 112, Second Paragraph Concerns

The present action rejects all the pending claims under § 112, second paragraph. as allegedly incomplete for omitting essential steps. In view of the amendment to claim 8, it is believed that the rejection is now moot.


E. Claims Objections

Lastly, the Action objects to claims 26-29, 31, 46 and 51 with the Action suggesting that the term “antigen’s” should be changed to “antigens”. In view of the claim cancellations and amendment it is believed that this rejection is now moot.

F. Conclusion

The foregoing is believed to be a complete response to the Office Communication. The Examiner is invited to contact the undersigned attorney at (512) 536-3055 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,


David L. Parker
Reg. No. 32,164
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.474.5201 (telephone)
512.536.4598 (fax)

Date: July 1, 2010